Based on these findings, ALKBH5 and RCN1 can be identified as potential therapeutic targets for skin keloids, and safe and effective targeted specific inhibitors of ALKBH5 and RCN1 can be screened and developed as targeted therapeutic agents for skin keloids to improve keloid formation in clinical patients. The gene discussed is RCN1; the disease is keloid.